Skip to main content
. 2019 Aug;31(4):673–685. doi: 10.21147/j.issn.1000-9604.2019.04.11

2.

Association of OC183B2 expression with clinicopathological features of OC patients (417 cases)

Characteristics n (%) OC183B2 expression [n (%)] χ2 P
Low (H-score ≤173.26) High (H-score >173.26)
OC, ovarian cancer; FIGO, International Federation of Gynecology and Obstetrics; CA125, cancer antigen 125.
Age at diagnosis (year) 1.486 0.223
 ≤50 149 (35.7) 52 (34.9) 97 (65.1)
 >50 266 (63.8) 109 (41.0) 157 (59.0)
 Unknown 2 (0.5)
Menopause 0.552 0.458
 No 149 (35.7) 56 (37.6) 93 (62.4)
 Yes 254 (60.9) 105 (41.3) 149 (58.7)
 Unknown 14 (3.4)
Histological subtypes 6.707 0.010
 Serous 368 (88.2) 135 (36.7) 233 (63.3)
 Nonserous 44 (10.6) 25 (56.8) 19 (43.2)
 Unknown 5 (1.2)
FIGO stage 2.702 0.440
 I 43 (10.3) 15 (34.9) 28 (65.1)
 II 34 (8.2) 9 (26.5) 25 (73.5)
 III 288 (69.1) 116 (40.3) 172 (59.7)
 IV 18 (4.3) 7 (38.9) 11 (61.1)
 Unknown 34 (8.2)
Histological grade 12.851 0.002
 Grade 1 24 (5.8) 1 (4.2) 23 (95.8)
 Grade 2 17 (4.1) 6 (35.3) 11 (64.7)
 Grade 3 330 (79.1) 135 (40.9) 195 (59.1)
 Unknown 46 (11.0)
Lymph node metastasis 0.053 0.818
 Negative 136 (32.6) 54 (39.7) 82 (60.3)
 Positive 75 (18.0) 31 (41.3) 44 (58.7)
 Unknown 206 (49.4)
Ascites (mL) 2.450 0.118
 <500 86 (20.6) 43 (50.0) 43 (50.0)
 ≥500 212 (50.8) 85 (40.1) 127 (59.9)
 Unknown 119 (28.5)
Preoperative CA125 (U/mL)
 <35 28 (6.7) 7 (25.0) 21 (75.0) 2.666 0.102
 ≥35 369 (88.5) 150 (40.7) 219 (59.3)
 Unknown 20 (4.8)
Residual tumor size (cm)
 ≤1 136 (32.6) 37 (27.2) 99 (72.8) 13.151 <0.001
 >1 59 (14.1) 32 (54.2) 27 (45.8)
 Unknown 222 (53.2)
Platinum resistance
 No 88 (21.1) 37 (42.0) 51 (58.0) 0.249 0.617
 Yes 35 (8.4) 13 (37.1) 22 (62.9)
 Unknown 294 (70.5)
Relapse
 No 119 (28.5) 29 (24.4) 90 (75.6) 16.584 <0.001
 Yes 141 (33.8) 69 (48.9) 72 (51.1)
 Unknown 157 (37.6)
Death 8.310 0.004
 No 176 (42.2) 57 (32.4) 119 (67.6)
 Yes 143 (34.3) 69 (48.3) 74 (51.7)
 Unknown 98 (23.5)